Vision Executives International Eye Care Recruitment
  • Home
  • About
  • Recruitment Services
  • Candidate Services
  • Vacancies
  • Eye Care News
  • Contact

Eye Care News

Latest june eyecare news:

23/6/2021

0 Comments

 
Aurion Biotech have announced their CEO, Greg Kunst. Aurion is developing a platform of advanced therapies to treat ocular diseases, starting with a cell therapy to treat corneal endothelial disease.

Biogen have announced that their BIIB111 treatment (timrepigene emparvovec) for choroideremia has not met its 1-year target in correcting visual acuity. They are reviewing the data for their treatment before deciding on the next steps for their gene therapy program.

EyeYon Medical have received CE Mark for its EndoArt after clinical trails proved its safety and efficacy for treating chronic corneal edema. EndoArt the first synthetic implant that replaces the human endothelium that the human body can’t regenerate. “We are proud to receive CE mark for our unique EndoArt implant, which is set to transform the way patients with chronic corneal edema are treated,” Nahum Ferera, co-Founder and CEO of EyeYon Medical.

Implandata Ophthalmic Products announced that their EYEMATE-SC biosensor has received a CE Mark. This works alongside their EYEMATE system which allows glaucoma to be monitored and managed digitally and remotely. “Obtaining CE mark for our less invasive EYEMATE-SC sensor as part of our validated EYEMATE system is another important step forward for the company to transform glaucoma care,” Max G. Ostermeier, CEO and Founder of Implandata.

LENZ Therapeutics is developing a proprietary eye drop formulation of aceclidine. This month they debuted a $47 million Series A financing to move these eyedrops forward toward an NDA submission for the treatment of presbyopia.
Picture
Ref: https://eyewire.news/articles/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/ https://eyewire.news/articles/lenz-therapeutics-debuts-with-47-million-series-a-financing/ https://eyewire.news/articles/eyeyon-medical-receives-ce-mark-for-its-endoart-implant-to-treat-chronic-corneal-edema/ https://eyewire.news/articles/greg-kunst-appointed-ceo-of-aurion-biotech/
0 Comments

​Does the eyewear sector need to become more sustainable?

9/6/2021

0 Comments

 
I recently stumbled across an article about Safilo’s premium sun lenses made out of a new sustainable material (40% biomass, with a 50% lower carbon footprint) and it got me thinking about the environmental impact of the eyewear industry.

I did some research and found out there’s a growing market for sustainable glasses frames – from bamboo, to recycled plastic – made by companies like Sea2see Eyewear, Pala Eyewear and SKRAP Skateboard Inc. Clearly consumers are caring more and more about the impact of their purchases and as such, many industries are under a lot of pressure to become more sustainable.

Judging by the amount of environmentally friendly eyewear options on the market, it seems that our industry is slow to catch up. It looks as though the eyewear sector needs to become more sustainable, so I created a poll on LinkedIn to see what you think: Who has the most influence to create change and help the sector become more sustainable?
0 Comments

positive gensight news  for retinitis pigmentosa  patients

2/6/2021

0 Comments

 
The improvement of a patient, who's had retinitis pigmentosa (RP) for 40 years, has been reported in a phase 1/2 clinical trial of GenSight Biologics' mutation-agnostic gene therapy. The treatment introduces genetic instructions from algae to the surviving layer of retina at the back of the eye. At first, the patient only responded to amber light, but recently identified white lines on crosswalks and identified items when wearing goggles which detect changes in light intensity.

RP causes vision loss through the death of light sensing cells and affects more than 2 million people worldwide. Optogenetics therapy uses light to control the activity of brain cells to restore vision. “The findings provide proof-of-concept that using optogenetic therapy to partially restore vision is possible" Prof Botond Roska, University of Basel.
​
There are several promising approaches aimed at restoring light for RP patients. In 2017, Spark Therapeutics, Inc., now part of Roche, won FDA approval for their mutation-specific RP gene therapy, Luxturna. It is uncertain whether a mutation-specific approach can be used for all patients, as the disease can be caused by changes in over 70 genes.
Picture
Ref: https://www.bbc.co.uk/news/health-57226572.amp https://www.fiercebiotech.com/biotech/mutation-agnostic-gene-therapy-triggers-partial-vision-recovery
0 Comments

    Author

    James Pickering is our Managing Director and an eye care recruitment expert who has developed an extensive client base and candidate network. He regularly writes articles about industry developments and has received numerous recommendations from industry leaders. You can also connect with James on LinkedIn to stay up to date on the latest eye care news.

    Archives

    December 2022
    October 2022
    September 2022
    August 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021

    Categories

    All
    Eye Care News

    RSS Feed

Picture

Location

Contact Us

Vision Executives Ltd
16 Market Place
Dewsbury
WF13 1AE
​United Kingdom

+44 (0) 1134900340
info@visionexecutives.com

Site Map

​Home
​
About
​Recruitment Services
​Candidate Services
Vacancies
Eye Care News
Contact
Vision Executives Ltd is a company registered in England & Wales. Company Number 13319387.
​Copyright © 2021 Vision Executives Ltd.
Click here to see our privacy policy.
  • Home
  • About
  • Recruitment Services
  • Candidate Services
  • Vacancies
  • Eye Care News
  • Contact